Download App

Log in to access Online Inquiry
Company Overview More
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company’s lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
CEO: McArthur Ph.D., James G.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > PEPG PepGen > Detailed Quotes

PEPG PepGen

11.650-0.260-2.18%
Close 05/18 20:00 ET
High
11.910
Open
11.860
Turnover
394.78K
Low
10.860
Pre Close
11.910
Volume
34.84K
Market Cap
239.57M
P/E(TTM)
Loss
52wk High
16.990
Shares
20.56M
P/E(Static)
Loss
52wk Low
9.280
Float Cap
83.88M
Bid/Ask %
0.00%
Historical High
16.990
Shs Float
7.20M
Volume Ratio
0.45
Historical Low
9.280
Dividend TTM
--
Div Yield TTM
--
P/B
-7.47
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.48%
Amplitude
8.82%
Avg Price
11.332
Lot Size
1
Float Cap
83.88M
Bid/Ask %
0.00%
Historical High
16.990
Shs Float
7.20M
Volume Ratio
0.45
Historical Low
9.280
Dividend TTM
--
P/B
-7.47
Dividend LFY
--
Turnover Ratio
0.48%
Amplitude
8.82%
Avg Price
11.332
Lot Size
1
Price Forecast

No Data

News

Comment